Product Program year 2024 Source: CMS Open Payments

Aklief

Drug Acne

NDC 0299-5935-30

Open in the dashboard

General payments

$6,792,661

43,983 payments

Research payments

$655,293

434 payments

Through program year 2024, $6,792,661 in general payments and $655,293 in research payments were reported against Aklief (Acne).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

8 rows
Year Kind Amount Payments
2024 General $752,352 344
2023 General $3,019,254 4,305
2022 General $747,526 8,898
2021 General $1,233,290 21,249
2021 Research $321,601 365
2020 General $992,881 8,836
2020 Research $333,692 69
2019 General $47,359 351

Breakdown

Who paid General payments · program years 2019–2024
  1. Galderma Laboratories, L.P. $6,781,961 43,981 payments
  2. Galderma Research & Development, LLC $10,700 2 payments
Top recipients General payments · program year 2024
  1. Edward Lain Dermatology · Austin, TX $33,084 4% · 22 payments
  2. Hilary Baldwin Dermatology · Brooklyn, NY $30,669 4% · 20 payments
  3. Julie Harper Dermatology · Birmingham, AL $18,200 2% · 4 payments
  4. Linda Stein Gold Dermatology · West Bloomfield, MI $17,000 2% · 2 payments
  5. Leon Kircik Dermatology · Lousiville, KY $12,800 2% · 2 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2024.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2024
  1. Dermatology $574,236 78% · 76 practitioners
  2. Physician Assistant, Medical Physician Assistant $38,530 5% · 10 practitioners
  3. Procedural Dermatology Dermatology $36,220 5% · 5 practitioners
  4. Physician Assistant $35,749 5% · 19 practitioners
  5. Pediatric Dermatology Dermatology $23,700 3% · 3 practitioners

The top 5 of 10 specialties; each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2024
  1. Texas $106,244 14% · 20 recipients
  2. New York $99,208 13% · 17 recipients
  3. California $68,188 9% · 15 recipients
  4. Florida $67,125 9% · 10 recipients
  5. Michigan $32,404 4% · 4 recipients

The top 5 of 31 states; each share is of general payments naming this product in 2024 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

47

Prescriptions dispensed, refills included

Drug cost

$32,021

Paid at the pharmacy, in all

Prescribers

3

With 11 or more claims of it

Medicare Part D drugs matched to AKLIEF, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Aklief Trifarotene Same name 3 47 $32,021

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

3 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Sherrie Straughn Dermatology GA 21 $14,452 None on record
Rita Stueder Nurse Practitioner KS 14 $9,247 None on record
Sarah Brunner Physician Assistant PA 12 $8,322 $32

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

43,983 general · 434 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record